Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 7/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.48 |
| ▸ | CDK4 | P11802 | 2/20 | 0.47 |
| ▸ | CCND1 | P24385 | 2/20 | 0.47 |
| ▸ | CCND2 | P30279 | 1/20 | 0.47 |
| ▸ | CCND3 | P30281 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | MERTK | Q12866 | 2/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5900490 | 0.75 | CCND1 (0.63) | CDK4CCND1 | |
| SCHEMBL5900351 | 0.75 | CCND1 (0.62) | CDK4CCND1 | |
| SCHEMBL4774992 | 0.74 | ADORA1 (0.45) | FGFR1MAPK8MAPK14CDK4CCND1 | |
| SCHEMBL14014588 | 0.74 | MAPK14 (0.83) | FGFR1MAPK8MAPK14LCKMAPK9 | |
| SCHEMBL4770644 | 0.72 | CTSS (0.43) | FGFR1CTSKCTSS | |
| SCHEMBL5900625 | 0.71 | CCNE1 (0.63) | CDK4CCND1 | |
| SCHEMBL24670367 | 0.71 | CCND1 (0.72) | FGFR1MAPK8CDK4CCND1CCND2 | |
| SCHEMBL3304431 | 0.71 | CCND1 (0.72) | FGFR1MAPK8CDK4CCND1CCND2 | |
| SCHEMBL14014590 | 0.70 | MAPK8 (0.84) | FGFR1MAPK8MAPK14LCKMAPK9 | |
| SCHEMBL14004183 | 0.70 | CTSS (0.41) | FGFR1CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449472-B2 | Methods of inhibiting p38 with substituted bicyclic pyrimidines | ROCHE PALO ALTO LLC (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449472-B2 | Methods of inhibiting p38 with substituted bicyclic pyrimidines | ROCHE PALO ALTO LLC (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449472-B2 | Methods of inhibiting p38 with substituted bicyclic pyrimidines | ROCHE PALO ALTO LLC (US) | 2008-11-11 | — | — | US | disclosed |
| US-7439247-B2 | Bicyclic pyridine and pyrimidine P38 kinase inhibitors | ROCHE PALO ALTOP LLC (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439247-B2 | Bicyclic pyridine and pyrimidine P38 kinase inhibitors | ROCHE PALO ALTOP LLC (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439247-B2 | Bicyclic pyridine and pyrimidine P38 kinase inhibitors | ROCHE PALO ALTOP LLC (US) | 2008-10-21 | — | — | US | disclosed |
| EP-1485390-B1 | BICYCLIC PYRIDINE AND PYRIMIDINE P38 KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-10-08 | — | — | EP | disclosed |
| EP-1485390-B1 | BICYCLIC PYRIDINE AND PYRIMIDINE P38 KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-10-08 | — | — | EP | disclosed |
| CN-100386328-C | Bicyclic pyridine and pyrimidine P38 kinase inhibitors | HOFFMANN LA ROCHE (CH) | 2008-05-07 | — | — | CN | disclosed |
| US-7091347-B2 | Bicyclic pyridine and pyrimidine p38 kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060084803-A1 | Bicyclic pyridine and pyrimidine P38 kinase inhibitors | CHEN JIAN J | 2006-04-20 | — | — | US | disclosed |
| US-20050288312-A1 | Bicyclic pyridine and pyrimidine p38 kinase inhibitors | CHEN JIAN J | 2005-12-29 | — | — | US | disclosed |
| CN-1639168-A | Bicyclic pyridine and pyrimidine P38 kinase inhibitors | HOFFMANN LA ROCHE (CH) | 2005-07-13 | — | — | CN | disclosed |
| EP-1485390-A1 | BICYCLIC PYRIDINE AND PYRIMIDINE P38 KINASE INHIBITORS | F. Hoffman-la Roche AG (CH) | 2004-12-15 | — | — | EP | disclosed |
| US-20030207900-A1 | Bicyclic pyridine and pyrimidine p38 kinase inhibitors | ROCHE PALO ALTO LLC | 2003-11-06 | — | — | US | disclosed |
| WO-2003074530-A1 | BICYCLIC PYRIDINE AND PYRIMIDINE P38 KINASE INHIBITORS | F. HOFFMAN-LA ROCHE AG (CH) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288312-A1 | Bicyclic pyridine and pyrimidine p38 kinase inhibitors | MAPK1, MAP3K1, MAP3K8 | FGFR1 587/4885MAPK8 14/4885MAPK14 46/4885 |
| US-20030207900-A1 | Bicyclic pyridine and pyrimidine p38 kinase inhibitors | MAPK1, MAP3K1, MAPKAPK2 | FGFR1 432/4885MAPK8 5/4885MAPK14 43/4885 |
| US-20060084803-A1 | Bicyclic pyridine and pyrimidine P38 kinase inhibitors | MAPK1, MAP3K1, MAP3K8 | FGFR1 587/4885MAPK8 14/4885MAPK14 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.